Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.

Turk AA, Wisinski KB.

Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16. Review.

PMID:
29660759
2.

The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients.

Esbona K, Yi Y, Saha S, Yu M, Van Doorn RR, Conklin MW, Graham DS, Wisinski KB, Ponik SM, Eliceiri KW, Wilke LG, Keely PJ.

Am J Pathol. 2018 Mar;188(3):559-573. doi: 10.1016/j.ajpath.2017.10.025.

PMID:
29429545
3.

Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα+ Mammary Carcinomas.

Shea MP, O'Leary KA, Fakhraldeen SA, Goffin V, Friedl A, Wisinski KB, Alexander CM, Schuler LA.

Cancer Res. 2018 Apr 1;78(7):1672-1684. doi: 10.1158/0008-5472.CAN-17-0985. Epub 2018 Jan 23.

PMID:
29363543
4.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
5.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.

Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM.

J Oncol Pharm Pract. 2018 Jul;24(5):348-353. doi: 10.1177/1078155217704989. Epub 2017 Apr 29.

PMID:
28457192
6.

Genomic Testing in the Management of Early-Stage Breast Cancer.

Ehsani S, Wisinski KB.

J Clin Outcomes Manag. 2017 May;24(5):229-238.

7.

Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers.

Tevaarwerk AJ, Hocking WG, Zeal JL, Gribble M, Seaborne L, Buhr KA, Wisinski KB, Burkard ME, Wiegmann DA, Sesto ME.

J Oncol Pract. 2017 May;13(5):e486-e495. doi: 10.1200/JOP.2016.018648. Epub 2017 Feb 21.

8.

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB.

Invest New Drugs. 2017 Jun;35(3):290-297. doi: 10.1007/s10637-016-0418-8. Epub 2016 Dec 21.

9.

Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.

Tevaarwerk AJ, Wisinski KB, O'Regan RM.

J Oncol Pract. 2016 Nov;12(11):1148-1156. Review.

PMID:
27858538
10.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ.

Invest New Drugs. 2017 Feb;35(1):87-94. doi: 10.1007/s10637-016-0403-2. Epub 2016 Nov 8.

11.

CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis.

Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, Wisinski KB, Huang W, Cai W, Pike JW, Yuan M, Ahlquist P, Xu W.

Cancer Cell. 2016 Jul 11;30(1):179-180. doi: 10.1016/j.ccell.2016.06.013. Epub 2016 Jul 11. No abstract available.

12.

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.

Wisinski KB, Xu W, Tevaarwerk AJ, Saha S, Kim K, Traynor A, Dietrich L, Hegeman R, Patel D, Blank J, Harter J, Burkard ME.

Clin Breast Cancer. 2016 Aug;16(4):256-61. doi: 10.1016/j.clbc.2016.03.005. Epub 2016 Mar 31.

13.

Role of the androgen receptor in triple-negative breast cancer.

Rampurwala M, Wisinski KB, O'Regan R.

Clin Adv Hematol Oncol. 2016 Mar;14(3):186-93. Review.

14.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.

Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G.

Clin Cancer Res. 2016 Jun 1;22(11):2659-67. doi: 10.1158/1078-0432.CCR-15-2365. Epub 2016 Mar 29.

15.

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

Oudin MJ, Jonas O, Kosciuk T, Broye LC, Guido BC, Wyckoff J, Riquelme D, Lamar JM, Asokan SB, Whittaker C, Ma D, Langer R, Cima MJ, Wisinski KB, Hynes RO, Lauffenburger DA, Keely PJ, Bear JE, Gertler FB.

Cancer Discov. 2016 May;6(5):516-31. doi: 10.1158/2159-8290.CD-15-1183. Epub 2016 Jan 25.

16.

Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer.

Choudhary A, Zachek B, Lera RF, Zasadil LM, Lasek A, Denu RA, Kim H, Kanugh C, Laffin JJ, Harter JM, Wisinski KB, Saha S, Weaver BA, Burkard ME.

Mol Cancer Ther. 2016 Jan;15(1):48-59. doi: 10.1158/1535-7163.MCT-15-0527. Epub 2015 Nov 19.

17.

Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer.

Shanle EK, Onitilo AA, Huang W, Kim K, Zang C, Engel JM, Xu W, Wisinski KB.

Am J Transl Res. 2015 Jul 15;7(7):1246-59. eCollection 2015.

18.

Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result.

Andreason M, Zhang C, Onitilo AA, Engel J, Ledesma WM, Ridolfi K, Kim K, Charlson JC, Wisinski KB, Tevaarwerk AJ.

J Community Support Oncol. 2015 May;13(5):195-201. doi: 10.12788/jcso.0135. No abstract available.

19.

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM.

Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65. doi: 10.2146/ajhp140591.

20.

Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.

Moussavi-Harami SF, Wisinski KB, Beebe DJ.

J Patient Cent Res Rev. 2014 Spring;1(2):85-92.

21.

Two Isoforms of the RNA Binding Protein, Coding Region Determinant-binding Protein (CRD-BP/IGF2BP1), Are Expressed in Breast Epithelium and Support Clonogenic Growth of Breast Tumor Cells.

Fakhraldeen SA, Clark RJ, Roopra A, Chin EN, Huang W, Castorino J, Wisinski KB, Kim T, Spiegelman VS, Alexander CM.

J Biol Chem. 2015 May 22;290(21):13386-400. doi: 10.1074/jbc.M115.655175. Epub 2015 Apr 10.

22.

Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer.

Ehsani S, Strigel RM, Pettke E, Wilke L, Tevaarwerk AJ, DeMartini WB, Wisinski KB.

Breast J. 2015 May-Jun;21(3):246-53. doi: 10.1111/tbj.12396. Epub 2015 Mar 17.

23.

Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?

Zelnak AB, Wisinski KB.

Cancer. 2015 Jan 1;121(1):17-24. doi: 10.1002/cncr.28815. Epub 2014 Jul 23. Review.

24.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH.

J Oncol Pharm Pract. 2015 Dec;21(6):416-24. doi: 10.1177/1078155214541572. Epub 2014 Jul 1.

25.

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2014 May;13(5):1356-68. doi: 10.1158/1535-7163.MCT-13-1021. Epub 2014 Mar 14.

26.

Leveraging electronic health record systems to create and provide electronic cancer survivorship care plans: a pilot study.

Tevaarwerk AJ, Wisinski KB, Buhr KA, Njiaju UO, Tun M, Donohue S, Sekhon N, Yen T, Wiegmann DA, Sesto ME.

J Oncol Pract. 2014 May;10(3):e150-9. doi: 10.1200/JOP.2013.001115. Epub 2014 Feb 11.

27.

CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis.

Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, Wisinski KB, Huang W, Cai W, Pike JW, Yuan M, Ahlquist P, Xu W.

Cancer Cell. 2014 Jan 13;25(1):21-36. doi: 10.1016/j.ccr.2013.12.007. Erratum in: Cancer Cell. 2016 Jul 11;30(1):179-180.

28.

Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer).

Rocque GB, Wisinski KB, Buhr KA, Froeschner JL, Jones N, Donohue S, Wiegmann D, Sesto ME, Tevaarwerk AJ.

J Cancer Educ. 2014 Jun;29(2):270-7. doi: 10.1007/s13187-013-0591-9.

29.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ.

Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26.

30.

Predictors of willingness to participate in window-of-opportunity breast trials.

Wisinski KB, Faerber A, Wagner S, Havighurst TC, McElroy JA, Kim K, Bailey HH.

Clin Med Res. 2013 Sep;11(3):107-12. doi: 10.3121/cmr.2013.1136. Epub 2013 Apr 11.

31.

Aromatase inhibitors and calcium absorption in early stage breast cancer.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE.

Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.

32.

Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ.

Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, Huang W, Xu W.

PLoS One. 2012;7(2):e30993. doi: 10.1371/journal.pone.0030993. Epub 2012 Feb 7.

33.

Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME.

Breast Cancer Res Treat. 2012 Jan;131(2):713-21. doi: 10.1007/s10549-011-1862-y. Epub 2011 Nov 8.

34.

Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.

Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, Baron J, Stram DO, Hayes MG.

J Exp Clin Cancer Res. 2010 May 25;29:57. doi: 10.1186/1756-9966-29-57.

35.

In the interest of full disclosure.

Burkard ME, Tevaarwerk AJ, Wisinski KB.

Lancet Oncol. 2010 Apr;11(4):314-5; author reply 315. doi: 10.1016/S1470-2045(10)70044-9. No abstract available.

PMID:
20359661
36.

Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.

Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B.

JAMA. 2008 Oct 1;300(13):1523-31. doi: 10.1001/jama.300.13.1523.

37.

The role of molecular markers in predicting response to therapy in patients with colorectal cancer.

Shankaran V, Wisinski KB, Mulcahy MF, Benson AB 3rd.

Mol Diagn Ther. 2008;12(2):87-98. Review.

PMID:
18422373
38.

Inoperable pancreatic cancer: standard of care.

Wisinski KB, Wahl AO, Small W Jr, Benson AB 3rd.

Oncology (Williston Park). 2007 Nov;21(13):1558-64; discussion 1565, 1570-2.

39.

Panitumumab in metastatic colorectal cancer.

Wisinski KB, Mulcahy MF, Benson AB 3rd.

Clin Adv Hematol Oncol. 2007 Jan;5(1 Suppl 1):10-1. No abstract available.

PMID:
17491586

Supplemental Content

Loading ...
Support Center